Comparative Pharmacology
Head-to-head clinical analysis: PLETAL versus ZONTIVITY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PLETAL versus ZONTIVITY.
PLETAL vs ZONTIVITY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cilostazol inhibits phosphodiesterase III (PDE3), increasing cAMP levels in platelets and vascular smooth muscle, leading to platelet inhibition and vasodilation.
ZONTIVITY (vorapaxar) is a protease-activated receptor-1 (PAR-1) antagonist that inhibits thrombin-induced and thrombin receptor agonist peptide (TRAP)-induced platelet aggregation. It does not directly inhibit thrombin activity but blocks thrombin-mediated platelet activation.
100 mg orally twice daily, administered at least 30 minutes before or 2 hours after meals.
1 mg orally once daily, with or without food.
None Documented
None Documented
Terminal half-life of cilostazol is approximately 11-13 hours; for active metabolites 3,4-dehydro-cilostazol (about 4-6 times more active) half-life is similar. Steady state achieved within a few days.
Terminal elimination half-life is approximately 10-12 hours in patients with normal renal function; prolonged in renal impairment.
Renal (approximately 77% as metabolites, <1% unchanged); fecal (approximately 18%)
Primarily as unchanged drug via renal excretion (approximately 80%) and fecal/biliary elimination (approximately 20%).
Category C
Category C
Antiplatelet Agent
Antiplatelet Agent